期刊
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
卷 82, 期 1, 页码 78-84出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2015.01.015
关键词
Streptococcus pneumoniae; Staphylococcus aureus; MRSA; Cephalosporin
资金
- Educational/Research Grant from Forest/Cerexa
A total of 4533 isolates from community-acquired respiratory tract infections (CARTIs) and 8446 from skin and skin structure infections (SSSIs) were consecutively collected in 149 US medical centers in 2013. Strains were susceptibility tested by broth microdilution method against ceftaroline and numerous comparators. Ceftaroline (MIC50/90, <= 0.015/0.12 mu g/mL) was more potent than ceftriaxone (MIC50/90, <= 0.06/1 mu g/mL) against Streptococcus pneumoniae and highly active against ceftriaxone-nonsusceptible strains (n = 201; MIC90, 0.25 mu g/mL). Ceftaroline was also very active against Haemophilus influenzae (MIC50/90, 0.008/0.015 mu g/mL), methicillin-susceptible (MIC50/90, 0.25/0.25 mu g/mL) and methicillin-resistant Staphylococcus aureus (MIC50/90, 1/1 mu g/mL), and beta-hemolytic streptococci (highest MIC, 0.03 mu g/mL). Ceftaroline exhibited good activity against non-extended-spectrum beta-lactamase (ESBL) phenotype isolates of Klebsiella spp. and Escherichia coli (96.7% susceptible and MIC90 of 0.25 mu g/mL for both) but limited activity against ESBL phenotype isolates. In summary, ceftaroline exhibited potent in vitro activity against a large collection of bacterial isolates causing CARTI and SSSI in US medical centers. (C) 2015 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据